Cormorant Asset Management’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.01M | Sell |
200,000
-50,000
| -20% | -$1M | 0.3% | 38 |
|
|
2025
Q1 | $4.92M | Hold |
250,000
| – | – | 0.37% | 38 |
|
|
2024
Q4 | $5.63M | Buy |
+250,000
| New | +$5.63M | 0.31% | 36 |
|
|
2023
Q4 | – | Sell |
-1,216,712
| Closed | -$16.6M | – | 51 |
|
|
2023
Q3 | $16.6M | Sell |
1,216,712
-719,421
| -37% | -$9.83M | 0.97% | 26 |
|
|
2023
Q2 | $39.5M | Hold |
1,936,133
| – | – | 2.21% | 10 |
|
|
2023
Q1 | $42.4M | Buy |
+1,936,133
| New | +$42.4M | 2.79% | 9 |
|